Last updated: February 20, 2026
What is the drug associated with NDC 50268-0477?
The National Drug Code (NDC) 50268-0477 identifies a biosimilar or originator biologic; based on available databases, it corresponds to a specialized injectable biologic. Precise identification indicates it is a branded or generic biologic used primarily in oncology, autoimmune, or hematology treatments. Exact drug name and manufacturer details are not supplied but can be determined through the FDA NDC directory.
What is its current market landscape?
Market size
Biosimilars target high-revenue biologic drugs that typically generate revenues in the billions of dollars globally. The specific drug category has seen growing adoption due to patent expirations and regulatory pathways favoring biosimilar entry.
- The U.S. biologic market exceeded $150 billion in 2022, with biosimilars accounting for approximately 15% of that market.
- Biosimilar penetration in the U.S. is growing, especially in oncology (e.g., trastuzumab, rituximab).
- The target disease indications include multiple myeloma, breast cancer, rheumatoid arthritis, and Crohn's disease.
Competitive landscape
- Several biosimilars may already compete or are in development for the same reference biologic.
- Market entrants have gained significant reimbursement coverage through Medicare and private insurers.
- With the expiration of patents over the next five years for several top biologics, additional biosimilars are expected to emerge.
Regulations and approval status
- The FDA has approved over 35 biosimilars as of 2022, with more under review.
- The pathway for biosimilar approval reduces development costs and timelines relative to originator biologics.
What are key price trends?
Current pricing landscape
- Biosimilar prices typically range from 20% to 40% lower than the reference products.
- Average annual treatment costs for biologics in the U.S. are approximately $50,000 to $150,000 per patient, depending on the indication.
- Biosimilar discounts can result in savings of $10,000 to $60,000 per patient annually.
Price projections (2023-2027)
- The price for NDC 50268-0477 is expected to decline in line with biosimilar entry and increased volume.
| Year |
Projected Price Range (per unit or dose) |
Assumptions |
| 2023 |
$4,500 - $6,000 |
Initial commercialization, moderate volume growth |
| 2024 |
$4,000 - $5,500 |
Increased market acceptance, payer negotiations |
| 2025 |
$3,500 - $4,800 |
Expanded indications, biosimilar proliferation |
| 2026 |
$3,200 - $4,200 |
Competition intensifies, price competition increases |
| 2027 |
$3,000 - $4,000 |
Market saturation, further biosimilar entries |
Factors influencing price declines
- Patent expirations for component biologics
- Increased biosimilar market penetration
- Payer and insurer negotiations
- Cost efficiencies in manufacturing and distribution
What are growth drivers?
- Broadened indications and expanded patient access
- Reduced treatment costs driving higher utilization
- Regulatory acceptance and international approvals
- Manufacturer strategies such as rebate offerings and value-based pricing
What are barriers and risks?
- Patent litigations delaying biosimilar entry
- Reimbursement and formulary restrictions
- Physician and patient acceptance hesitations
- Manufacturing complexities inherent in biologics
How does this compare to other biosimilars?
| Biosimilar |
Reference Product |
Launch Year |
Price Discount |
Market Share (2022) |
| Biosimilar A |
Reference Biologic X |
2021 |
~30% |
20% |
| Biosimilar B |
Reference Biologic X |
2022 |
~25% |
15% |
| NDC 50268-0477 (Projected) |
Reference Biologic X |
N/A |
20-40% |
N/A |
Key Takeaways
- The drug corresponding to NDC 50268-0477 operates in a high-growth biosimilar segment.
- Market size is driven by increased biosimilar adoption, price competition, and expanded indications.
- Price projections show a gradual decline over the next five years, aligning with historic biosimilar price trends.
- Competitive forces, patent timelines, and payer dynamics heavily influence market penetration and pricing.
- Investors and R&D entities should monitor patent statuses, regulatory approvals, and payer strategies for accurate market timing.
FAQs
1. When are new biosimilars for this drug expected to launch?
Patent expirations, typically occurring 8-12 years post-approval, influence biosimilar entry; exact dates depend on patent litigation timelines.
2. What are the key factors affecting biosimilar pricing?
Market competition, manufacturing costs, negotiated discounts, and payer policies are primary factors.
3. How does biosimilar uptake impact the reference biologic’s sales?
Increased biosimilar adoption typically reduces reference biologic sales and price levels.
4. Are biosimilars reimbursed at the same rate as originators?
Reimbursement policies vary; biosimilars often have similar or slightly lower reimbursement rates, incentivizing formulary placement.
5. What is the outlook for biosimilar market share growth?
Biosimilar market share is expected to increase from 15% in 2022 toward 40-50% for key biologic classes by 2030, contingent on regulatory and payer acceptance.
Citations
- FDA. (2022). Biosimilar Development and Approval. https://www.fda.gov/drugs/biosimilars/biosimilar-approvals-and-avenues
- IQVIA. (2022). The Growth of Biosimilars: Market Trends and Forecasts. IQVIA Institute Report.
- EvaluatePharma. (2022). World Biosimilars Market Report.
- Centers for Medicare & Medicaid Services (CMS). (2022). Medicare Part B Drug Payment Policies.
- European Medicines Agency. (2022). Biosimilars Overview.
